The FDA has approved bevacizumab-awwb (Mvasi) as a treatment for multiple cancers. The drug has been approved as a biosimilar to its reference biologic, bevacizumab (Avastin), but it has not been approved as an interchangeable product.
The FDA has approved bevacizumab-awwb (Mvasi) as treatment for multiple cancers. The drug has been approved as a biosimilar to its reference biologic, bevacizumab (Avastin), but it has not been approved as an interchangeable product.
Mvasi, developed via a partnership between Amgen and Allergan, is approved for the treatment of adult patients suffering from either colorectal cancer, glioblastoma, cervical cancer, or non-squamous non—small cell lung cancer. Specifically, the approved indications include:
FDA Commissioner Scott Gottlieb, MD, said in a statement, “Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower healthcare costs and increase access to important therapies." He added that the FDA will continue on its track to bring new biosimilar medications to the market quickly “through a process that makes certain that these new medicines meet the FDA’s rigorous gold standard for safety and effectiveness.”
The approval follows 2 months after a unanimous (17-0) vote by the FDA’s Oncologic Drugs Advisory Committee to approve the drug.
The evidence submitted for FDA review included structural and functional characterization of bevacizumab-awwb, along with animal study data, pharmacokinetic and pharmacodynamic study data in humans, clinical immunogenicity data, and other safety and efficacy data.
The reference bevacizumab is manufactured by Genentech and was approved in February 2004.
AJMC
In the following video, Bruce A. Feinberg, DO, discusses the adoption of biosimilars among community oncologists with 's Center for Biosimilars.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen